ESA Data On Survival Benefit In Renal Transplant Grafts Are Insufficient - Medicare Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
The MedCAC review focused narrowly on the benefit of using ESAs - Amgen's Aranesp (darbepoetin alfa) and Centocor Ortho Biotech's Procrit (epoetin alfa) - in transplant graft survival for kidney patients.
You may also be interested in...
Drug Pricing Critic Peter Bach Named Chair Of Medicare Advisory Panel
But appointment unlikely to signal new emphasis on prescription drugs for MedCAC.
CMS Maintaining The Status Quo For ESAs In Chronic Renal Disease
The Centers for Medicare and Medicaid Services has decided not to proceed with a national coverage determination for erythropoiesis-stimulating agents in patients with chronic kidney disease, according to a proposed decision memo released March 16.
CMS Maintaining The Status Quo For ESAs In Chronic Renal Disease
The Centers for Medicare and Medicaid Services has decided not to proceed with a national coverage determination for erythropoiesis-stimulating agents in patients with chronic kidney disease, according to a proposed decision memo released March 16.